EMJ Rheumatology 3 [Suppl 4] . 2016

| View in Fullscreen

In this issue

Prof Gerd Horneff opened the symposium with a summary of the recent advances in the understanding of the role of interleukin (IL)-1β in the pathogenesis of autoinflammatory (AI) diseases. Prof Angelo Ravelli then discussed the concept of ‘treat-to-target’ in systemic juvenile idiopathic arthritis (SJIA) and the various tools that can be used for monitoring treatment response. Dr Jasmin B Kümmerle-Deschner followed with an overview of the efficacy and safety data from the β-Confident Registry of patients with cryopyrin-associated periodic syndromes (CAPS) receiving treatment with canakinumab. Prof Fabrizio De Benedetti concluded with an overview of the up-and-coming data in the field of AI diseases. The objectives of the symposium were to summarise new insights in the pathogenesis of AI diseases including the role of IL-1β; to evaluate the use of anti-IL-1β and other treatment options for AI diseases; to describe the
treat-to-target concept and recognise the potential of a tight disease control strategy in patients with SJIA; to integrate new knowledge on the long-term use of canakinumab in patients with CAPS based on the latest β-Confident Registry data; and to discuss management strategies in patients with AI diseases.